Neomorph Raises $100 Million in Series B Funding
Neomorph, a biotechnology company based in San Diego, California, has successfully closed a $100 million Series B funding round. The financing was led by Deerfield Management, with participation from Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, and Binney Street Capital of Dana-Farber Cancer Institute.
Co-Founder, President, and CEO Phil Chamberlain highlighted the significance of this funding, saying, "This financing is a testament to the science, strategy, and team we have built at Neomorph, and it provides us with the capital to execute on our most important near-term priorities."
Focus on Cancer Treatment and Molecular Glue Degraders
Neomorph specializes in the development of molecular glue degraders, a novel approach to targeting previously undruggable proteins. These degraders are designed to address significant unmet medical needs, particularly in cancer treatment.
The funds from the Series B round will primarily support the ongoing Phase 1/2 trial of NEO-811. This trial focuses on treating locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC). In addition, the financing will aid in advancing Neomorph's broader pipeline of molecular glue degraders.
Strategic Use of Funds
The capital raised will be strategically utilized to generate clinical data from the NEO-811 trial, which is expected to inform further development of the treatment. Neomorph aims to continue its efforts in developing innovative treatments for patients with significant unmet needs.
Welcoming New and Continuing Investors
Neomorph's CEO expressed gratitude for the continued support from its founding investor, Deerfield Management, and welcomed the new investment partners. This round of funding marks a significant step for Neomorph as it continues to develop its innovative pipeline and work towards delivering effective treatments for patients.
With this substantial financial backing, Neomorph is well-positioned to make strides in addressing challenging medical conditions through its cutting-edge biotechnology solutions.